Author

Fumio Tanaka

PRETREATMENT SERUM MONOCYTE CHEMOATTRACTANT PROTEIN-1, BUT NOT TROUGH LEVEL, AS A PREDICTOR OF LONG-TERM OUTCOME BY USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE
PRETREATMENT SERUM MONOCYTE CHEMOATTRACTANT PROTEIN-1, BUT NOT TROUGH LEVEL, AS A PREDICTOR OF LONG-TERM OUTCOME BY USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE

Fumio Tanaka  et al.

IS USTEKINUMAB EFFECTIVE IN CROHN'S DISEASE PATIENTS WITH PARADOXICAL SKIN REACTIONS CAUSED BY TUMOR NECROSIS FACTOR-ALPHA INHIBITORS?
IS USTEKINUMAB EFFECTIVE IN CROHN'S DISEASE PATIENTS WITH PARADOXICAL SKIN REACTIONS CAUSED BY TUMOR NECROSIS FACTOR-ALPHA INHIBITORS?

Fumio Tanaka  et al.

Item 1 - 2 / 2
1